First case of acute cholestatic hepatitis attributed to oseltamivir in a young girl with ah1n1 influenza
Keywords:
Influenza, oseltamivir, acute hepatitis, H1N1Abstract
Oseltamivir caryboxylase is a potent inhibitor of the enzyme neuramidase of the influenza virus particle and it is active against both influenza A and B viruses. Oseltamivir is indicated for therapy or post-exposure prevention of influenza A and B. Side effects are uncommon and include mild nausea, gastrointestinal upset, dizziness and headache. Despite its widespread use, oseltamivir has not been associated with clinically apparent liver injury. To the best of our knowledge, this is the first case report in the literature linking the development of acute hepatitis to the consumption of oseltamivir in a patient suffering from influenza H1N1 infection.
References
1. LiverTox: Clinical and Research Information on DrugInduced Liver Injury [Internet]. Bethesda
(MD): National Institute of Diabetes and Diges-
A. Mastroianni et al.
tive and Kidney Diseases; 2012-. Oseltamivir. [Updated 2014 Jan 24].
2. Polakos NK, Cornejo JC, Murray DA, et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol 2006; 168(4): 1169-78; quiz 1404-5.
3. Esper RC, Péres Bustos E, Arroyo SO, Saavedra JA, Uribe M. Liver involvement in severe human AH1N1. Ann Hepatol 2019; 9: 107-111.
4. Yingying C. Abnormal liver chemistry in patients with influenza A H1N1. Liver Intern 2011; 31(6): 902. doi: 10.1111/j.1478-3231 .2011.02519.x.
5. Whitworth JR, Mack CL, O’Connor JA, Narkewicz MR, Mengshol S, Sokol RJ. Acute hepatitis and liver failure associated with influenza A infection in children. J Pediatr Gastroenterol Nutr 2006; 43(4): 536-8.
6. Nonaka K, Matsuda Y, Kakizaki M, et al. Acute liver failure associated with influenza A virus infection: an autopsy case report. Jpn J Infect Dis 2019; 72(5): 347-349. doi: 10.7883/yoken. JJID.2018.494.
7. Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respir
Viruses 2012; 6(3): e2-e5. doi: 10.1111/j.1750-
2659.2011.00287.x
8. Jefferson T, Jonessen M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348: g2545. doi: https:// doi.org/10.1136/bmj.g2545.
9. Antipov EA. Pokryshevskaya EB. The effects of adverse drug reactions on patients’ satisfaction: evidence from publicly available data on Tamiflu (oseltamivir). Int J Med Inform 2019; 125: 30-6. doi: https://doi.org/10.1016/j. ijmedinf.2019.02.005.
10. Hama R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis (Lond) 2016; 48(9): 651-60. doi:
10.1080/23744235.2016.1189592.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.